Conference abstract · 2017
Conference abstractPublished 20 Feb 2017
From human vaccines for viral diseases to those ones for oncogenic viruses and tumor antigens
Foundation de Beaumont Bonelli for Cancer Research, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Variola major, the virus that causes the smallpox, lethal virus in the 30% of the cases, was eradicated in 1979 in the human species, thanks to a capillary vaccination on global scale. Recently, the World Health Organization declared that India and Southeast Asia are polio free; really a great achievement since the vaccine for polio, an infectious disease that can cause paralysis, was certificated safe and useful only 60 years ago. Last year over 800 million doses of combination vaccines are going to be used to vaccinate Chinese children whereas more than 20 million children worldwide do not receive one or more important vaccinations that would protect them from at least one preventable disease. Research is badly needed to develop strategies to communicate the importance of vaccinations to uncertain parents. The 2008 San Diego measles outbreak costed over 10.000 dollars for each infection in comparisons to the total cost to contain the outbreak (approximately 124.000 dollars). Even if there are rare cases of vaccine damage, the research to facilitate vaccination must be done to prevent diseases. The vaccine for HBV virus, responsible for hepatitis B infection is able to prevent 50% of all liver cancers. Human papilloma viruses (HPV) have been correlated with the cervical cancer (genotypes 16 and 18 particularly oncogenic in humans): the USA Food and Drug Administration in 2006 released the first vaccine against HPV. Long years of research were required for busting the new system to fight cancer. Research is going to obtain the complete sequence by proteomics approaches, in order to achieve adequate antigen preparations that might be used to generate assays for a specific anticancer vaccine. Finally, the ability of the immune system to recognize a tumor-associated antigen, thus enabling development of a vaccine approach for therapeutic application, represents a main target of this field of research.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 7 Dec 2015
Antigenic difference of HN protein between the vaccine strain and the challenge strain of Newcastle disease virus significantly affects virus shedding and transmission
Conference abstract · 21 Oct 2019
Comparison of protection and viral shedding following vaccination with homologous and heterologous Newcastle disease virus strains
Conference abstract
Creation of highly efficient recombinant viral vectors for development of prime-boost vaccines: Matrix protein gene variants of two antigenically distinct serotypes of vesicular stomatitis virus are ideal vaccine vectors
Conference abstract · 6 Dec 2018
Tumor associated antigen as potential vaccine for cancer patients
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectInfectious Diseases
- SubjectOncology & Cancer
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Giulio Tarro”
